Skip to main content
. Author manuscript; available in PMC: 2014 Apr 17.
Published in final edited form as: Cancer Metastasis Rev. 2008 Dec;27(4):589–613. doi: 10.1007/s10555-008-9157-4
Drug Imaging Study Reference
CA4P PET- Perfusion [66]
Razoxane PET - Perfusion and blood volume [67]
SU5416 PET - Perfusion and metabolism [68]
Bevacizumab CT - Perfusion [88]
MEDI-522 CT - Blood flow, blood volume, PS, MTT [89]
AZD2171 DCE-MRI – Decreases in Ktrans [134,135]
SU11248 DCE-MRI – Decreases in Ktrans & fPV 24h post-treatment [136]
AG-013736 DCE-MRI – Decreases in Ktrans 48h post-treatment [137]
PTK787/ZK222584 DCE-MRI – Dose dependent reduction in Ktrans & AUC [138,139]
AEE788 DCE-MRI – Decrease in area under enhancement curve [140]
ZD6474 DCE-MRI – Dose dependent reduction in Ktrans [141]
HuMV833 DCE-MRI – Decreases in Ktrans 48h post-treatment [142]
Endostatin DCE-MRI – No consistent change in Ktrans or ve [143]